<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01117584</url>
  </required_header>
  <id_info>
    <org_study_id>1941-CL-0005</org_study_id>
    <secondary_id>2009-013881-25</secondary_id>
    <nct_id>NCT01117584</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus</brief_title>
  <acronym>BALANCE</acronym>
  <official_title>Phase IIb, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12-Week Treatment With ASP1941 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy, safety and tolerability of a 12-week treatment of 4 doses of ASP1941
      compared to placebo in combination with metformin in adult patients with Type 2 Diabetes
      Mellitus who have inadequate glycemic control on metformin alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2010</start_date>
  <completion_date type="Actual">April 1, 2011</completion_date>
  <primary_completion_date type="Actual">April 1, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c at Week 12</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose (FPG) at Week 12</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of target goal (HbA1c &lt;7.0%) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of target goal (HbA1c &lt;6.5%) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">343</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>ASP1941 lowest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1941 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1941 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1941 highest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1941</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>ASP1941 high dose</arm_group_label>
    <arm_group_label>ASP1941 low dose</arm_group_label>
    <arm_group_label>ASP1941 highest dose</arm_group_label>
    <arm_group_label>ASP1941 lowest dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>ASP1941 high dose</arm_group_label>
    <arm_group_label>ASP1941 low dose</arm_group_label>
    <arm_group_label>ASP1941 highest dose</arm_group_label>
    <arm_group_label>ASP1941 lowest dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has been diagnosed with Diabetes Mellitus type 2 (T2DM) for at least 6 months

          -  Subject has inadequate glycemic control indicated by an HbA1c level between 7.0% and
             9.5% at start of the run-in period at Visit 1 AND does not meet any of the FPG
             discontinuation criteria

          -  Subject has been on a stable dose of at least 1500 mg/day metformin monotherapy for at
             least 6 weeks prior to Visit 1

          -  Subject is on a stable diet and exercise program (for at least 6 weeks prior to Visit
             1) and is willing to remain on this program for the duration of the study

          -  Subject has a body mass index (BMI) 20 - 45 kg/m2 at Visit 1

          -  Female subject of childbearing potential has a negative serum pregnancy test (human
             chorionic gonadotropin [hCG]) at Visit 1 and agrees to use an acceptable form of
             contraception throughout the duration of the study OR is at least 1 year
             post-menopausal (defined as amenorrhea for at least 1 year) or surgically sterile.
             Male study subjects should be advised to use a male condom in addition to having their
             partner use another acceptable method during the study and for 3 months after the last
             dose

        Exclusion Criteria:

          -  Subject has any known complication of T2DM indicating a late disease state that in the
             investigator's opinion should preclude the subject from participation

          -  Subject has type 1 diabetes mellitus

          -  Subject is in need of insulin therapy or has received insulin within 3 months prior to
             Visit 1, with the exception of acute use of &lt;7 days

          -  Subject has a serum creatinine higher than upper limit of normal range at Visit 1

          -  Subject has an alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)
             higher than 3 times upper limit of normal range or has a total bilirubin more than 2
             times upper limit of normal at Visit 1

          -  Subject has a urinary microalbumin/creatinine ratio above or equal to 300 mg/g at
             Visit 1

          -  Subject has a symptomatic urinary tract infection (UTI) or symptomatic genital
             infection at Visit 1 or during the placebo run-in period, including just prior to
             randomization at Visit 2

          -  Subject has persistent, uncontrolled severe hypertension as indicated by a systolic
             blood pressure &gt;180 mmHg or a diastolic blood pressure of &gt;110 mmHg taken in a sitting
             position after 5 minutes of rest on at least 2 measurements (within 30 minutes of each
             other) at Visit 1

          -  Subject has a significant cardiovascular disease, such as myocardial infarction or a
             vascular intervention (e.g. angioplasty or stent) within 3 months prior to Visit 1, or
             history of heart failure (New York Heart Association [NYHA] Class III IV)

          -  Subject is known to have hepatitis or be a carrier of hepatitis B surface antigen
             (HBsAg), hepatitis C virus (HCV) antibody (enzyme linked immunosorbent assay [ELISA]
             plus confirmatory test), or is known positive for human immunodeficiency virus (HIV)
             HIV-1 and/or HIV 2

          -  Subject is currently receiving an excluded medication (loop-diuretics or systemic
             corticosteroids) or has received any other oral anti-diabetic drug except for
             metformin within 3 months prior to Visit 1

          -  Subject has history of lactic acidosis

          -  Subject has a history of drug or alcohol abuse/dependency within 12 months prior to
             Visit 1 as defined in the Diagnostic and Statistical Manual-IV (DSM-IV)

          -  Subject has had a malignancy in the last 5 years, except for adequately treated basal
             or squamous cell carcinoma of the skin or carcinoma in situ of the cervix

          -  Female subject who is pregnant, lactating or pre-menopausal with positive serum
             pregnancy test (hCG) at Visit 1 or has an intention of becoming pregnant

          -  Subject has an unstable medical or psychiatric illness

          -  Subject has known or suspected hypersensitivity to ASP1941 or any components of the
             formulations used

          -  Subject has previously received ASP1941

          -  Subject is concurrently participating in another drug study or has received an
             investigational drug within 30 days (or the limit set by national law, whichever is
             longer) prior to Visit 1

          -  Subject has any concurrent illness which, in the opinion of the investigator, may
             interfere with treatment or evaluation of safety or completion of this study

          -  In the investigator's judgment, the subject is unable to adhere to the treatment
             regimen, protocol procedures or study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ude Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyongyos</city>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mako</city>
        <zip>6900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ancona</city>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sienna</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chrzanow</city>
        <zip>32-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>30-015</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>30-550</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kutno</city>
        <zip>99-330</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>03-003</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-127</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <zip>500269</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <zip>500365</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>010492</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>011234</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <zip>020275</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <zip>20045</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Constanta</city>
        <zip>900675</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Craiova</city>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lasi</city>
        <zip>700547</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ploiesti</city>
        <zip>100018</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ploiesti</city>
        <zip>100163</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sibiu</city>
        <zip>550371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridgeshire</city>
        <zip>CB8 9PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reading</city>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/study.aspx?ID=2</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <disposition_first_submitted>April 29, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 29, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 1, 2012</disposition_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>ASP1941</keyword>
  <keyword>diabetes</keyword>
  <keyword>metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

